Characteristics of observed cohorts reported in 15 studies of patients requiring mechanical ventilation after hematopoietic stem cell transplantation
| Author, year . | N . | Days from HSCT to MV (median/range) . | Male (%) . | Age (y) (median/mean) . | Type of transplantation . | Percent receiving HSCT for hematologic malignancy/disorder* . | |
|---|---|---|---|---|---|---|---|
| Allogeneic (%) (% matched†/% other)‡ . | Autologous (%) . | ||||||
| Crawford et al, 19882 | 232 | 29/(1-155) | 65 | NR/27 | 95 (64/31) | 5 | 932-153 |
| Torrecilla et al, 19884 | 16 | NR | 75 | 25/28 | 100 | 0 | 100 |
| Denardo et al, 198921 | 44 | NR | NR | NR/30 | 100 | 0 | NR |
| Afessa et al,2-155199229 | 27 | NR | 63 | 35/36 | 66 | 34 | 100 |
| Crawford and Peterson, 19921 | 348 | 392-154/(0-172) | 59 | 30/NR | 85 (58/27) | 15 | 97 |
| Paz et al, 199330 | 28 | NR | 53 | NR/37 | 78 | 22 | 97 |
| Faber-Langendoen et al, 19938 | 191 | 52/(0-2324) | 56 | 33/NR | 83 | 17 | NR |
| Rubenfeld and Crawford, 19963 | 865 | 252-159/(0-243) | 59 | ∼352-160 | 94 | 6 | 982-164 |
| Epner et al,2-155199632 | 71 | NR | 62 | NR/46 | 75 (69/6) | 25 | 100 |
| Hollmig et al, 19975 | 10 | NR | 60 | 36/37 | 100 | 0 | 100 |
| Jackson et al,2-155199831 | 92 | NR | 55 | 37/NR | 64 (42/22) | 36 | >92 |
| Price et al,2-161199823 | 48 | NR | 54 | 43/NR | 63 (51/12) | 37 | 83 |
| Ewig et al,2-155199828 | 50 | NR | 58 | NR/36 | 82 | 18 | 100 |
| Shorr et al,2-155199933 | 17 | NR/(3-11) | 29 | NR/48 | 0 | 100 | 20 |
| Huaringa et al, 200027 | 60 | 30/NR | 45 | NR/39 | 57 | 43 | 82-902-162 |
| Author, year . | N . | Days from HSCT to MV (median/range) . | Male (%) . | Age (y) (median/mean) . | Type of transplantation . | Percent receiving HSCT for hematologic malignancy/disorder* . | |
|---|---|---|---|---|---|---|---|
| Allogeneic (%) (% matched†/% other)‡ . | Autologous (%) . | ||||||
| Crawford et al, 19882 | 232 | 29/(1-155) | 65 | NR/27 | 95 (64/31) | 5 | 932-153 |
| Torrecilla et al, 19884 | 16 | NR | 75 | 25/28 | 100 | 0 | 100 |
| Denardo et al, 198921 | 44 | NR | NR | NR/30 | 100 | 0 | NR |
| Afessa et al,2-155199229 | 27 | NR | 63 | 35/36 | 66 | 34 | 100 |
| Crawford and Peterson, 19921 | 348 | 392-154/(0-172) | 59 | 30/NR | 85 (58/27) | 15 | 97 |
| Paz et al, 199330 | 28 | NR | 53 | NR/37 | 78 | 22 | 97 |
| Faber-Langendoen et al, 19938 | 191 | 52/(0-2324) | 56 | 33/NR | 83 | 17 | NR |
| Rubenfeld and Crawford, 19963 | 865 | 252-159/(0-243) | 59 | ∼352-160 | 94 | 6 | 982-164 |
| Epner et al,2-155199632 | 71 | NR | 62 | NR/46 | 75 (69/6) | 25 | 100 |
| Hollmig et al, 19975 | 10 | NR | 60 | 36/37 | 100 | 0 | 100 |
| Jackson et al,2-155199831 | 92 | NR | 55 | 37/NR | 64 (42/22) | 36 | >92 |
| Price et al,2-161199823 | 48 | NR | 54 | 43/NR | 63 (51/12) | 37 | 83 |
| Ewig et al,2-155199828 | 50 | NR | 58 | NR/36 | 82 | 18 | 100 |
| Shorr et al,2-155199933 | 17 | NR/(3-11) | 29 | NR/48 | 0 | 100 | 20 |
| Huaringa et al, 200027 | 60 | 30/NR | 45 | NR/39 | 57 | 43 | 82-902-162 |
ICU indicates intensive care unit; HSCT, hematopoietic stem cell transplantation; MV, mechanical ventilation; NR, not reported.
Category includes leukemias, lymphomas, multiple myeloma, and bone marrow disorders such as myelodysplastic syndrome, and aplastic anemia.
Donor and recipient related and/or major human leukocyte antigens (HLA) identical.
Donor and recipient unrelated and/or HLA major antigen mismatch.
Proportion of patients with hematologic malignancy in entire cohort undergoing HSCT.
Cohort characteristics available only for larger cohort of patients requiring ICU admission who did not necessarily require MV.
Mean value.
Based on control group only.
Age estimated as midpoint between within group median values.
Proportion of patients with hematologic malignancy in entire cohort (personal communication, G. Rubenfeld, March 6, 2000).
Study performed on a subset of validation cohort.
Underlying malignancy described for only 55 of 60 patients.